Exelixis Posts 28% Q4 Revenue Gain, Closes Enrollment in Two Phase 3 Trials
Exelixis reported robust Q4 2025 revenue growth driven by a 28% increase in CABOMETYX sales and narrowed its net loss by 12%. The company also closed enrollment in two Phase 3 trials targeting renal and hepatic cancers and unveiled a new strategic collaboration to advance its immuno-oncology pipeline.
1. Q4 Financial Results
Exelixis delivered Q4 2025 revenue of $508 million, up 28% year-over-year, primarily driven by increased CABOMETYX prescriptions in renal cell carcinoma. The company reduced its net loss by 12% sequentially, reflecting improved operating efficiencies and cost controls.
2. Strategic Pipeline Developments
The company announced completion of patient enrollment in two pivotal Phase 3 trials—one in advanced renal cell carcinoma and another in hepatocellular carcinoma—paving the way for topline data in mid-2026. Additionally, Exelixis entered a strategic collaboration to co-develop a next-generation immuno-oncology candidate, expanding its late-stage pipeline.